Immunocore (NASDAQ:IMCR – Get Free Report) and Sera Prognostics (NASDAQ:SERA – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Immunocore and Sera Prognostics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunocore | 1 | 4 | 6 | 1 | 2.58 |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
Immunocore presently has a consensus price target of $56.38, suggesting a potential upside of 75.68%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 170.94%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, analysts clearly believe Sera Prognostics is more favorable than Immunocore.
Earnings and Valuation
This table compares Immunocore and Sera Prognostics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunocore | $400.02 million | 4.13 | -$35.51 million | ($0.37) | -86.73 |
| Sera Prognostics | $70,000.00 | 1,144.02 | -$31.93 million | ($0.67) | -3.03 |
Sera Prognostics has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Immunocore and Sera Prognostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunocore | -4.20% | -4.54% | -1.66% |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
Volatility and Risk
Immunocore has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.
Insider & Institutional Ownership
84.5% of Immunocore shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Comparatively, 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
